With FOLFIRI for mCRC.
4 mg/kg IV Q2W.
100 mg/4 mL, 200 mg/8 mL
None listed.
Leukopenia (78%), Diarrhea (69%), Neutropenia (67%), Proteinuria (62%), Stomatitis (50%), Fatigue (48%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
No formal studies.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Recombinant VEGF decoy receptor.
t1/2: ~6 days.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Zaltrap has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Zaltrap (ziv-aflibercept) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Recombinant VEGF decoy receptor.
Leukopenia (78%), Diarrhea (69%), Neutropenia (67%), Proteinuria (62%), Stomatitis (50%), Fatigue (48%) Leukopenia 78% Diarrhea 69% Neutropenia 67% Proteinuria 62% Stomatitis 50% Fatigue 48%